Ceo
CurrentHy2Care develops the CartRevive(R) hydrogel implant for the treatment of cartilage defects.As CEO, I have created the team, with which we developed the therapy towards clinical stage. We have successfully completed the first phase of our EU trial, are actively recruiting patients for phase 2. We received the H2020 EIC Acellerator blended financing, and have obtained FDA Breakthrough Device Designation in the US.